DelveInsight's "DARZALEX Market Size, Forecast, and Market Insight Report" highlights the details around DARZALEX, a human ...

DARZALEX has significant market potential as a leading monoclonal antibody for multiple myeloma treatment. Its approval in various combinations for both newly diagnosed and relapsed/refractory ...

The FDA has accepted the resubmitted BLA for linvoseltamab for patients with relapsed/refractory multiple myeloma.

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...

Alternative splicing (AS) of pre-mRNA plays a crucial role in tissue-specific gene regulation, with disease implications due to splicing defects. Predicting and manipulating AS can therefore uncover ...

Zevor-cel was approved by China's National Medical Products Administration (NMPA). <li /> As of December 31, 2024, ...

Fintel reports that on March 17, 2025, Leerink Partners initiated coverage of Nurix Therapeutics (NasdaqGM:NRIX) with a ...

EsoBiotec develops therapies that engineer immune cells within the body, eliminating the need for patients to go through lymphodepletion and reinfusion.

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related mortality worldwide. Current treatment modalities are few or ...

Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström Macroglobulinemia First-in-class Bruton’s tyrosine kinase (BTK) degrader NX-5948 ...

Selective protein degradation by the ubiquitin–proteasome pathway is a fundamental regulatory strategy that fulfils essential roles in various cellular processes. In recognition of the central ...